Insider · CIK 0002041972
Jakap Koo
Files at APUS (Apimeds Pharmaceuticals US, Inc.). First filing May 14, 2025, latest May 14, 2025.
In brief
Jakap Koo files SEC Form 4 as director at APUS (Apimeds Pharmaceuticals US, Inc.). Since May 14, 2025, Jakap Koo has reported 1 open-market buy worth $57k and 0 open-market sells worth $0, the latest filed on May 14, 2025.
A track record needs three past buys with six months of prices behind them; Jakap Koo has 0, so none is measured yet.
The newest scored trade: bought $57k of APUS on May 12, 2025, filed May 14, 2025, scored 37 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
APUS: Apimeds Pharmaceuticals US, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 37Weak | Apimeds Pharmaceuticals US, Inc. | $57k 28,500 shares | +5% | - |
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 11, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | AGrant or award Stock Option (right to buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Nov 13, 2025 |
| Oct 15, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | AGrant or award Stock Option (right to buy)derivative | +3,000 | $0.00 | $0 | 3,000 | Oct 17, 2025 |
| May 16, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | AGrant or award Stock Option (right to buy)derivative | +5,780 | $0.00 | $0 | 5,780 | May 20, 2025 |
| May 12, 2025 | APUS Apimeds Pharmaceuticals US, Inc. | POpen-market purchase Common Stock, par value $0.01 per share | +28,500 | $1.99 | $57k | 643,885 | May 14, 2025 |
Questions about Jakap Koo
Answered from the filings on this page, as of the latest one.
Is Jakap Koo buying or selling?
Not in the last 12 months. Jakap Koo's latest open-market trade on SEC Form 4 was bought $57k of APUS on May 12, 2025.
How did Jakap Koo's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jakap Koo has 0.
Where does Jakap Koo file Form 4?
Jakap Koo has filed Form 4 at APUS (Apimeds Pharmaceuticals US, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.